Experience during the first year after implementation shows that interest in preexposure prophylaxis is high and that it can easily be integrated into existing HIV prevention programs.
Although combination FTC/tenofovir received FDA approval in 2012 for preexposure prophylaxis (PrEP) use, debate continues on how best to scale up this new HIV preventive strategy. Researchers recently described experiences with PrEP uptake and delivery during the first year after approval in three different settings in San Francisco: a municipal sexually transmitted disease (STD) clinic, a private health maintenance organization, and an HIV-specific reproductive health program.
Almost half of the eligible individuals offered PrEP (261/531) in the STD clinic initiated PrEP, with initiation more likely among high-risk individuals and those with prior knowledge of PrEP. PrEP-related stigma (e.g., belief that PrEP would increase risk-taking beha…
Reviewing Author
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes
DisclosuresConsultant/Advisory BoardUNAIDS; WHO; Bill and Melinda Gates Foundation, Population Council
Grant/Research SupportNIH; National Institute of Allergy and Infectious Diseases; Tides Foundation/MAC AIDS Fund; USAID; South African National Research Foundation; European Union; South African Medical Research Council
Editorial BoardsNew England Journal of Medicine; AIDS Reviews; AIDS Research and Human Retroviruses; mBio; Indian Journal of Medical Research; JAIDS: Journal of Acquired Immune Deficiency Syndromes